CJC-1295 With DAC specifications and research profile
Specifications summary
| Designation | Albumin-binding hGRF(1-29) analogue |
|---|---|
| Also known as | CJC-1295 with DAC |
| Sequence / composition | Tetrasubstituted hGRF(1-29) analogue with a reactive albumin-binding group |
| Strength | 5mg × 10 vials |
| Presentation | 10-vial case |
| Purity | 99%+ HPLC |
| Storage | Store refrigerated at 2-8 C, protected from light. |
| COA | Batch document added when available |
Description and research context
CJC-1295 with DAC is a modified hGRF(1-29) analogue designed to bind serum albumin through an added reactive group, extending stability relative to unmodified GHRH fragments.
Published work characterised albumin conjugation, rat pituitary-cell bioactivity and growth-hormone secretory patterns. Results depend on the species, model and exposure design.
Applications in research
- Albumin-conjugation and peptide-stability assays
- GHRH-receptor and pituitary-cell response models
- DAC versus no-DAC analogue comparisons
Precautions and interpretation
For controlled laboratory research only. Not for human or veterinary use. The cited findings come from specific biochemical, cellular, structural or preclinical models and must not be treated as usage guidance or evidence of a defined outcome outside those models.
Research references
CJC-1295 With DAC research record
Clear product, batch, storage, dispatch and document information for this 10-vial case.
Research context
An albumin-binding hGRF(1-29) analogue studied in GHRH-receptor, peptide-stability and growth-hormone secretory-pattern models.
Product record
The listing identifies the presentation, specification, storage record, dispatch status, and COA availability for the relevant product or batch.
Use restriction
For laboratory research use only. Not for human or veterinary consumption. No use instructions or therapeutic guidance is provided.